Efficacy of once-weekly dulaglutide on HbA1c reduction in East Asian patients with T2DM: subgroup analysis according to potential influencing factors

被引：0
|
作者：
Peng, Yongde [1 ]
Zhang, Bin [2 ]
Hou, Jianing [2 ]
机构：
[1] Shanghai First Peoples Hosp, Shanghai, Peoples R China
[2] Lilly Suzhou Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
DIABETES-METABOLISM RESEARCH AND REVIEWS | 2019年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1524615
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Percentage of patients with Type 2 diabetes and baseline HbA1c ≥7.5% treated with once weekly dulaglutide, or exenatide twice daily, achieving HbA1c decrease of ≥1% and weight loss of ≥3% at 26 weeks in the Assessment of Weekly Administration of Dulaglutide in Diabetes (AWARD) 1 and 5 studies
    Adetunji, O.
    Tahbaz, A.
    Nicolay, C.
    Khunti, K.
    DIABETIC MEDICINE, 2015, 32 : 77 - 78
  • [42] Based on HbA1c Analysis: Bone Mineral Density and Osteoporosis Risk in Postmenopausal Female with T2DM
    Gao, Lei
    Liu, Ying
    Li, Min
    Wang, Yan
    Zhang, Wei
    JOURNAL OF CLINICAL DENSITOMETRY, 2024, 27 (01)
  • [43] In T2DM, weekly insulin icodec did not differ from daily glargine for reducing HbA1c or significant/severe hypoglycemia
    Griffin, Tomas P.
    Dinneen, Sean F.
    ANNALS OF INTERNAL MEDICINE, 2021, 174 (03) : JC34 - JC34
  • [44] Phase 1 Study of Safety, Tolerability, PK, and PD of Once-Weekly Basal Insulin Fc (BIF) in Japanese Patients with T2DM
    Ohwaki, Kenji
    Furihata, Kenichi
    Nasu, Risa
    Oura, Tomonori
    Imori, Makoto
    DIABETES, 2021, 70
  • [45] Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD-11
    Frias, Juan P.
    Bonora, Enzo
    Cox, David A.
    Bethel, M. Angelyn
    Kwan, Anita Y. M.
    Raha, Sohini
    Malik, Raleigh E.
    DIABETES OBESITY & METABOLISM, 2021, 23 (12): : 2819 - 2824
  • [46] Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis
    Miao Yu
    Guo Yue Yuan
    Bin Zhang
    Hai Ya Wu
    Xiao Feng Lv
    Diabetes Therapy, 2020, 11 : 1147 - 1159
  • [47] Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2)
    Yan Li
    Ling Li
    Yong De Peng
    Guang Yao Song
    Shan Dong Ye
    Li Ying Du
    Jia Ning Hou
    Qiu He Ji
    Diabetes Therapy, 2019, 10 : 1435 - 1452
  • [48] Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2)
    Li, Yan
    Li, Ling
    Peng, Yong De
    Song, Guang Yao
    Ye, Shan Dong
    Du, Li Ying
    Hou, Jia Ning
    Ji, Qiu He
    DIABETES THERAPY, 2019, 10 (04) : 1435 - 1452
  • [49] Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis
    Yu, Miao
    Yuan, Guo Yue
    Zhang, Bin
    Wu, Hai Ya
    Lv, Xiao Feng
    DIABETES THERAPY, 2020, 11 (05) : 1147 - 1159
  • [50] Real-World A1C Changes and Prescribing Provider Types among T2DM Patients Initiating Treatment with Once-Weekly (OW) Semaglutide
    Frazer, Monica S.
    Swift, Caroline
    Sargent, Andrew
    Leszko, Michael
    Buysman, Erin
    Alvarez, Sara B.
    Noone, Joshua
    Gamble, Cory L.
    DIABETES, 2022, 71
12345